DTIL
- Precision BioSciences, Inc.
()
Overview
Company Summary
Precision BioSciences, Inc. is a biotechnology company that specializes in developing gene editing technologies. It utilizes its proprietary ARCUS genome editing platform to engineer a diverse range of genetic modifications in various organisms. The company's primary focus is on the development of gene therapies for treating life-threatening diseases, particularly genetic disorders and cancers.
Precision BioSciences' ARCUS platform utilizes a unique and highly specific enzyme called the ARC nuclease to precisely edit genes within a cell's DNA. This technology allows for targeted modifications, insertions, or deletions of genetic material, providing potential therapeutic solutions that were previously not feasible.
One of the key advantages of Precision BioSciences' ARCUS platform is its ability to create non-viral, off-the-shelf gene therapies. By avoiding the use of viruses for gene delivery, the company aims to reduce potential safety concerns and enable more efficient production and distribution of its therapies.
The company has several ongoing preclinical and clinical programs targeting specific diseases. These include the development of allogeneic CAR T-cell therapies for various cancers, gene knockouts for treating genetic diseases like sickle cell disease and Duchenne muscular dystrophy, and targeted gene insertions for rare metabolic diseases.
Precision BioSciences also collaborates with other pharmaceutical and biotech companies, leveraging its gene editing expertise to develop novel therapies and advance their partners' drug discovery programs. These collaborations help the company expand its reach and potentially capture additional revenue streams.
Overall, Precision BioSciences strives to leverage its gene editing technologies to revolutionize the treatment of genetic diseases and improve patient outcomes.